BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235-251, vi. [PMID: 15831271 DOI: 10.1016/j.cld.2004.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
3 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 386] [Article Influence: 34.9] [Reference Citation Analysis]
4 Owen WE, Roberts RF, Roberts WL. Performance characteristics of the LiBASys® des-gamma-carboxy prothrombin assay. Clinica Chimica Acta 2008;389:183-5. [DOI: 10.1016/j.cca.2007.11.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ress AL, Wagle R, Pichler M. Multi-omics in prognosis of hepatocellular carcinoma. Ann Transl Med 2015;3:2. [PMID: 25705634 DOI: 10.3978/j.issn.2305-5839.2014.12.07] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
7 Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 2012;19:594-600. [PMID: 22762144 DOI: 10.1111/j.1365-2893.2011.01577.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
8 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
9 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
10 Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology. 2007;244:898-906. [PMID: 17709836 DOI: 10.1148/radiol.2443061520] [Cited by in Crossref: 207] [Cited by in F6Publishing: 183] [Article Influence: 13.8] [Reference Citation Analysis]
11 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
12 Mizuno H, Honda M, Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E, Kaneko S. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma. Liver Int 2012;32:1146-55. [PMID: 22372738 DOI: 10.1111/j.1478-3231.2012.02778.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
13 Choi BI, Lee JM. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: Imaging diagnosis and staging of hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2010;17:369-73. [DOI: 10.1007/s00534-009-0227-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
14 Lun Yau AH, Galorport C, Coffin CS, Ko HH. Hepatocellular carcinoma screening practices among patients with chronic hepatitis B by Canadian gastroenterologists and hepatologists: An online survey. CanLivJ 2019;2:199-209. [DOI: 10.3138/canlivj.2019-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
17 Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, Sirlin C. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Radiol Clin North Am 2017;55:1197-209. [PMID: 28991560 DOI: 10.1016/j.rcl.2017.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
18 Mendy M, Walton R. Molecular pathogenesis and early detection of hepatocellular carcinoma--perspectives from West Africa. Cancer Lett. 2009;286:44-51. [PMID: 19523756 DOI: 10.1016/j.canlet.2009.04.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
19 Xiong Y, Xie CR, Zhang S, Chen J, Yin ZY. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res 2019;11:5745-56. [PMID: 31303788 DOI: 10.2147/CMAR.S197455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
20 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
22 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
23 Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, Abdel-Hamid M, Gouda I, Ezzat S, Kyselova Z. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808-1813. [PMID: 19223512 DOI: 10.1158/1078-0432.ccr-07-5261] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
24 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 233] [Article Influence: 19.6] [Reference Citation Analysis]
26 Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012-1024. [PMID: 17006932 DOI: 10.1002/hep.21328] [Cited by in Crossref: 200] [Cited by in F6Publishing: 216] [Article Influence: 12.5] [Reference Citation Analysis]
27 Marrero CR, Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 2007;38:612-20. [DOI: 10.1016/j.arcmed.2006.09.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
28 Ressom HW, Varghese RS, Goldman L, An Y, Loffredo CA, Abdel-Hamid M, Kyselova Z, Mechref Y, Novotny M, Drake SK, Goldman R. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res 2008;7:603-10. [PMID: 18189345 DOI: 10.1021/pr0705237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
29 Simon K, Serafińska S, Pazgan-Simon M. Surveillance programmes for early detection of hepatocellular carcinoma. Contemp Oncol (Pozn) 2012;16:295-9. [PMID: 23788898 DOI: 10.5114/wo.2012.30057] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
31 Goldman R, Ressom HW, Abdel-Hamid M, Goldman L, Wang A, Varghese RS, An Y, Loffredo CA, Drake SK, Eissa SA. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007;28:2149-2153. [PMID: 17724376 DOI: 10.1093/carcin/bgm177] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
32 Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779-792. [PMID: 21357378 DOI: 10.1158/1055-9965] [Cited by in F6Publishing: 75] [Reference Citation Analysis]
33 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
34 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
35 Prieto PA, Cha CH. DKK1 as a serum biomarker for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2013;2:127-128. [PMID: 24570929 DOI: 10.3978/j.issn.2304-3881.2012.10.12] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
36 Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, Mehta AS, Marrero J, Gish R, Norton PA. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark 2012;11:161-71. [PMID: 23144154 DOI: 10.3233/CBM-2012-00276] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
37 Rodrigues T, Boike JR. Biliary Strictures: Etiologies and Medical Management. Semin Intervent Radiol 2021;38:255-62. [PMID: 34393335 DOI: 10.1055/s-0041-1731086] [Reference Citation Analysis]
38 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
39 Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 431-47. [DOI: 10.1007/978-1-59745-565-7_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118. [PMID: 19362088 DOI: 10.1053/j.gastro.2009.04.005] [Cited by in Crossref: 392] [Cited by in F6Publishing: 356] [Article Influence: 30.2] [Reference Citation Analysis]
41 Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76. [PMID: 19925500 DOI: 10.1111/j.1365-2036.2009.04200.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 9.9] [Reference Citation Analysis]
42 Cui Z, Yu X, Guo L, Wei Y, Zheng S, Li W, Chen P, Zhu J, Peng J. Combined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinoma. Dis Markers. 2013;35:915-923. [PMID: 24427779 DOI: 10.1155/2013/907394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-799. [PMID: 22374994 DOI: 10.1158/1055-9965.epi-11-1005] [Cited by in Crossref: 157] [Cited by in F6Publishing: 92] [Article Influence: 15.7] [Reference Citation Analysis]
44 Wu CS, Yen CJ, Chou RH, Li ST, Huang WC, Ren CT, Wu CY, Yu YL. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. PLoS One 2012;7:e39466. [PMID: 22808038 DOI: 10.1371/journal.pone.0039466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
45 Hu QY, Zhang S, Zhang CM. MicroRNAs as diagnostic biomarkers for hepatocellular carcinoma: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2015; 23(8): 1314-1322 [DOI: 10.11569/wcjd.v23.i8.1314] [Reference Citation Analysis]
46 Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009;3:597-605. [PMID: 19966928 DOI: 10.1517/17530050903266830] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
47 El-shazly SF, Eid MA, El-sourogy HA, Attia GF, Ezzat SA. Evaluation of Serum Dna Integrity as a Screening and Prognostic Tool in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. Int J Biol Markers 2010;25:79-86. [DOI: 10.1177/172460081002500204] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
48 Zhou DX, Zheng LY, Qu HX, Yu FH, Zou SS, Hong Y, Tan YX, Wang H, Hu HP, Wang HY. Identification and differential expression of human carcinoma-associated antigens in hepatocellular carcinoma tissues. Exp Biol Med (Maywood) 2013;238:167-75. [PMID: 23576798 DOI: 10.1177/1535370212474599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]